Zenith Capital ZHCLF Stock
Zenith Capital Price Chart
Zenith Capital ZHCLF Financial and Trading Overview
| Zenith Capital stock price | 0.3 USD |
| Previous Close | 0.1 USD |
| Open | 0.05 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.05 - 0.05 USD |
| 52 Week Range | 0.0003 - 0.19 USD |
| Volume | 2.1K USD |
| Avg. Volume | 10.28K USD |
| Market Cap | 64.41K USD |
| Beta (5Y Monthly) | 630.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.21 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZHCLF Valuation Measures
| Enterprise Value | 25.02M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -8.402 |
Trading Information
Zenith Capital Stock Price History
| Beta (5Y Monthly) | 630.63 |
| 52-Week Change | -99.59% |
| S&P500 52-Week Change | 15.77% |
| 52 Week High | 0.19 USD |
| 52 Week Low | 0.0003 USD |
| 50-Day Moving Average | 0.06 USD |
| 200-Day Moving Average | 0.07 USD |
ZHCLF Share Statistics
| Avg. Volume (3 month) | 10.28K USD |
| Avg. Daily Volume (10-Days) | 48.8K USD |
| Shares Outstanding | 161.02M |
| Float | 156.62M |
| Short Ratio | N/A |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | April 30, 2026 |
| Most Recent Quarter (mrq) | July 31, 2026 |
| Next Fiscal Year End | April 30, 2027 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -13.12% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -2978000 USD |
| Net Income Avi to Common (ttm) | -9142000 USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 199K USD |
| Total Cash Per Share (mrq) | 0.001 USD |
| Total Debt (mrq) | 25.16M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.01 |
| Book Value Per Share (mrq) | -0.18 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2515000 USD |
| Levered Free Cash Flow (ttm) | -4435875 USD |
Profile of Zenith Capital
| Country | United States |
| State | AB |
| City | Calgary |
| Address | 4820 Richard Road S.W. |
| ZIP | T3E 6L1 |
| Phone | 587-390-7865 |
| Website | https://www.zenithepigenetics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Zenith Capital Corp., a biotechnology investment company, develops bromodomain (BET) inhibitors for the treatment of cancer and other disorders with unmet medical needs in Canada. The company's lead compound ZEN-3694, which is in Phase 2b clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as for NUT carcinoma, solid tumors, breast and metastatic cancer, ovarian and colorectal cancer, lung and pancreatic cancer, and malignant peripheral nerve sheath tumors. It has collaborations with the National Cancer Institute, Astellas Pharma, Newsoara Biopharma Co., University of California San Francisco, Merck & Co., Memorial Sloan Kettering Cancer Center, University of Pittsburgh Medical Center Hillman Cancer Center, Bristol Myers Squibb, Dana-Farber - Harvard Cancer Center, Eli Lilly and Company, University of Texas MD Anderson Cancer Center, Yale University Cancer Center, U.S. Army Medical Research and Development Command, Sidney Kimmel Comprehensive Cancer Center, University of Alabama Birmingham, and Pfizer. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.
Q&A For Zenith Capital Stock
What is a current ZHCLF stock price?
Zenith Capital ZHCLF stock price today per share is 0.3 USD.
How to purchase Zenith Capital stock?
You can buy ZHCLF shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zenith Capital?
The stock symbol or ticker of Zenith Capital is ZHCLF.
Which industry does the Zenith Capital company belong to?
The Zenith Capital industry is Biotechnology.
How many shares does Zenith Capital have in circulation?
The max supply of Zenith Capital shares is 161.02M.
What is Zenith Capital Price to Earnings Ratio (PE Ratio)?
Zenith Capital PE Ratio is now.
What was Zenith Capital earnings per share over the trailing 12 months (TTM)?
Zenith Capital EPS is -0.21 USD over the trailing 12 months.
Which sector does the Zenith Capital company belong to?
The Zenith Capital sector is Healthcare.
